We congratulate Dr. Margit Mahlapuu to the VINNOVA grant of 1 MSEK for her research on the development of a new treatment for type 2 diabetes!
Type 2 diabetes (T2D) has grown at an exponential rate. There are more than 382 million people living with T2D and 592 million expected to be affected in 2035.
Dr. Margit Mahlapuu have with GU Ventures as coordinator allocated 1 MSEK from SWElifes. The project is run in collaboration with Sprint Bioscience as industrial partners.
Read more about the news here.